The revenue decline was expected as fiscal 2025 included large upfront payments from licensing deals. Focus shifts to REDEMPLO commercial ramp and the sHTG sNDA review under the STAR program, with a potential U.S. launch in Q2 2027. The new credit facility improves financial flexibility. Monitor the transition report (10-QT) for the period ending December 31, 2026.
Drugs in focus
ARWR drug pipeline →Redemplo
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (US, FCS); Phase 3 (severe hypertriglyceridemia) ongoing; EU under review
- Time to market
- Already approved and launched in the US (FDA, November 2025) for FCS. EU decision expected ~2026; SHTG label expansion ~2027 if the Phase 3 readout is positive.
- Next catalyst
- None dated
What to watchThe main re-rating event for ARWR is the Phase 3 severe-hypertriglyceridemia (SHTG) topline readout, expected around mid-September 2026 per trial estimates, SHTG is a far bigger market than the ultra-rare FCS indication Redemplo was approved for. Also watch the Aug 4, 2026 earnings call for the first real Redemplo launch revenue commentary, the pending EU decision after the April 2026 CHMP opinion, and direct competition from Ionis' olezarsen (which had its own FDA decision date for SHTG on June 30, 2026).
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $47.78entry
- T+1 · 17h ago −7.47%α −5.56% · $44.21
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arrowhead Pharmaceuticals reported fiscal 2026 full-year revenue of $450.8M, down 45.6% from $829.4M in fiscal 2025, and a GAAP net loss of $724.2M ($5.11 per share) versus a $1.6M loss in the prior year. The revenue decline was driven by the absence of large upfront licensing fees that boosted fiscal 2025, while operating expenses rose sharply due to a $215M priority review voucher acquisition and higher R&D and SG&A costs. The company highlighted strong REDEMPLO commercial momentum, FDA STAR program entry for the sHTG sNDA, and positive clinical data across multiple pipeline programs.
Key Financial Metrics
Key Facts
- Fiscal 2026 revenue $450.8M, down 45.6% from $829.4M in fiscal 2025.
- GAAP net loss attributable to Arrowhead of $724.2M ($5.11 per diluted share) versus a $1.6M loss in fiscal 2025.
- Operating expenses rose to $1.158B from $731.1M, including a $215M acquired priority review voucher.
- Total cash resources (cash, equivalents, and securities) were $1.193B at September 30, 2026, up from $919.4M a year earlier.
- REDEMPLO (plozasiran) launch in FCS continued with 950 cumulative new-to-brand prescriptions and 50-60 weekly prescriptions.
- FDA granted plozasiran entry into the STAR pilot program for the sHTG sNDA, enabling a 6-month priority review.
- Company refinanced its credit facility with a new $400M senior secured term loan at SOFR plus 5.50%, replacing a 15% facility.
- Board approved a change in fiscal year end from September 30 to December 31, effective January 1, 2027.
- Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in sHTG met primary and all secondary endpoints.
- Interim data for ARO-DIMER-PA (dual PCSK9/APOC3) and ARO-MAPT (tau for Alzheimer's) showed positive results.
Financial Impact
Revenue decline of $378.6M YoY; net loss worsened by $722.6M; operating cash flow not separately disclosed but total cash resources increased by $273.6M.
Risk Factors
- Revenue heavily dependent on partnership milestones and REDEMPLO commercial uptake; sHTG approval and launch are key catalysts.
- Operating losses are large and growing; cash burn rate needs monitoring despite the $1.2B cash position.
- Fiscal year change creates a transitional reporting period, potentially complicating comparisons.
- Clinical pipeline (ARO-DIMER-PA, ARO-MAPT, zodasiran) is early-stage; regulatory and commercial risks remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000879407-26-000077 |
| Document: arwr-20261112.htm | 0000879407-26-000077 |
| Document: 0000879407-26-000077-index-headers.html | 0000879407-26-000077 |
| Document: 0000879407-26-000077-index.html | 0000879407-26-000077 |
| Document: 0000879407-26-000077.txt | 0000879407-26-000077 |
| 8-K Data (Synthetic) | 0000879407-26-000077 |
Track record
7 reports on ARWR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Viewing Entry $47.78 to $44.21 Now $44.21 +7.47% ▲ +7.47% +5.56% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $57.46 to $58.16 Now $44.21 −23.06% ▲ +1.22% +0.91% vs SPY
- Nov 4, 202612d ago 8-K Bullish 5/10 Entry $61.65 to $57.46 Now $44.21 −28.29% ▼ −6.80% −2.39% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $59.53 to $61.65 Now $44.21 +25.73% ▼ −3.56% −1.91% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $82.76 to $82.85 Now $44.21 −46.58% ▲ +0.11% −0.74% vs SPY
- Aug 20, 202612w ago Insider Cluster Neutral 2/10 Entry $87.11 to $86.73 Now $44.21 −49.25% ▼ −0.44% −0.14% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $81.04 to $81.82 Now $44.21 −45.45% ▲ +0.96% +0.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers